Updated: April 17, 2021 10:54:38 am
An experimental antiviral drug, MK-4482, significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from scientists from the US National Institutes of Health (NIH), and published in the journal Nature Communications.
MK-4482, delivered orally, is now in human clinical trials. Remdesivir is provided intravenously, making its use primarily limited to clinical settings.
The scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2.
These data suggest that MK-4482 treatment potentially could mitigate high-risk exposures to SARS-CoV-2, and might be used to treat established SARS-CoV-2 infection alone or possibly in combination with other agents.
Source: NIH (US)
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.